There are currently 73 active clinical trials seeking participants for Atrial Fibrillation research studies. The states with the highest number of trials for Atrial Fibrillation participants are Florida, California, Ontario and Texas.
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
NCT05357690
Recruiting
The purpose of this study is to test if a nerve block procedure called a stellate ganglion block can help decrease the chance of atrial fibrillation after surgery. Atrial fibrillation is the abnormal, fast beating of the upper chambers of the heart. Stellate ganglion blockade has shown to decrease other types of abnormal heart rhythms as well as decrease the chance of atrial fibrillation.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
05/10/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Atrial Fibrillation
Register for Updates
Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation
NCT05190679
Recruiting
This is a prospective, case-control study that seeks to learn about the role of genetics in early onset atrial fibrillation (AF) and if genetic testing can be used to improve how the investigators treat atrial fibrillation. The study will enroll 225 participants. Eligible participants will have undergone sequencing for arrhythmia and cardiomyopathy (CM) genes. Based on those results, participants will be recruited for an outpatient research visit with testing that includes cardiac MRI, rest/stre... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
05/08/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Atrial Fibrillation
Register for Updates
Renal Denervation + PVI vs PVI Alone for Persistent AF
NCT05116384
Recruiting
Pulmonary vein isolation (PVI) is the cornerstone of ablation for atrial fibrillation (AF). Increased cardiac sympathetic stimulation can facilitate AF and reduction can be accomplished by renal artery denervation (RDN). The recently completed randomized trial, ERADICATE-AF, convincingly demonstrated that RDN plus PVI resulted in a reduction in recurrent incident AF for uncontrolled hypertensives. This is a randomized controlled pilot trial, "To Evaluate Renal Artery Denervation in Addition to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: University of Rochester, Short Hills, New Jersey
Conditions: Atrial Fibrillation
Register for Updates
Pericardiotomy in Cardiac Surgery
NCT06486636
Recruiting
PRINCE is an international, multicentre, randomized controlled trial of posterior pericardiotomy in patients without a history of atrial fibrillation (AF) or flutter undergoing cardiac surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Weill Cornell Medicine, New York, New York +2 locations
Conditions: Atrial Fibrillation, Atrial Flutter, Cardiac Events
Register for Updates
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
NCT06802081
Recruiting
This is a single center randomized double blind controlled study of patients (BMI\> 30 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/02/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Atrial Fibrillation, Obesity
Register for Updates
PULSED AF Post-Approval Study
NCT06578104
Recruiting
PULSED AF PAS is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Southcoast Health System, Fall River, Massachusetts +7 locations
Conditions: Atrial Fibrillation
Register for Updates
The CONFORM Pivotal Trial
NCT05147792
Recruiting
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Grandview Medical Center, Birmingham, Alabama +56 locations
Conditions: Atrial Fibrillation, Stroke
Register for Updates
SIMPLAAFY Clinical Trial
NCT06521463
Recruiting
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Grandview Medical Center, Birmingham, Alabama +49 locations
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy.
NCT04703166
Recruiting
To evaluate the progression of atrial myopathy through wearable devices and cardiac imaging.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
04/14/2025
Locations: Tulane University School of Medicine, New Orleans, Louisiana
Conditions: Atrial Fibrillation
Register for Updates
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
NCT05836987
Recruiting
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
04/14/2025
Locations: Banner University, Phoenix, Arizona +83 locations
Conditions: Atrial Fibrillation
Register for Updates
320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation Before AF Ablation.
NCT06308094
Recruiting
This study explores the relationship between myocardial fibrosis and patient outcomes in Atrial Fibrillation (AF), specifically after catheter ablation. It aims to use Cardiac CT, an accessible tool, to measure left ventricular extracellular volume (ECV) as an indicator of fibrosis. The study will assess if higher ECV levels correlate with increased risks of AF recurrence, hospitalization, and poor cardiac function recovery. Positive findings could make ECV a key factor in deciding AF treatment... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/10/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Atrial Fibrillation
Register for Updates
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698
Recruiting
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Affinity Hospital dba Grandview Medical Center, Birmingham, Alabama +49 locations
Conditions: Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Register for Updates